Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Innovent Signs $267 Million Deal for Novel Anti-Inflammatory Candidate

publication date: Sep 28, 2021

Suzhou Innovent Bio acquired China rights to an atopic dermatitis therapy developed by Denmark's Union Therapeutics in a $267 million agreement. Innovent will pay $20 million upfront and make up to $247 million in milestones, plus royalties. The candidate, orismilast, is a next-gen PDE4 inhibitor with broad anti-inflammatory properties that has shown positive proof of concept data orally in psoriasis and topically in atopic dermatitis. Orismilast is being developed as a best- or first-in-class treatment option in both diseases. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.